Trial Outcomes & Findings for Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia (NCT NCT00711269)
NCT ID: NCT00711269
Last Updated: 2022-04-12
Results Overview
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
COMPLETED
PHASE3
460 participants
Baseline and Week 6 [Last Observation Carried Forward (LOCF)]
2022-04-12
Participant Flow
Participant milestones
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
Placebo was administered orally twice daily.
|
Risperidone Group
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
131
|
131
|
133
|
65
|
|
Overall Study
COMPLETED
|
87
|
83
|
83
|
51
|
|
Overall Study
NOT COMPLETED
|
44
|
48
|
50
|
14
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Baseline characteristics by cohort
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=125 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=129 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=129 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=64 Participants
Risperidone 2 mg was administered orally twice daily.
|
Total
n=447 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
45.6 years
STANDARD_DEVIATION 14.48 • n=39 Participants
|
45.7 years
STANDARD_DEVIATION 13.51 • n=41 Participants
|
46.0 years
STANDARD_DEVIATION 12.85 • n=35 Participants
|
44.8 years
STANDARD_DEVIATION 12.59 • n=31 Participants
|
45.6 years
STANDARD_DEVIATION 13.44 • n=146 Participants
|
|
Sex: Female, Male
Female
|
50 Participants
n=39 Participants
|
47 Participants
n=41 Participants
|
57 Participants
n=35 Participants
|
29 Participants
n=31 Participants
|
183 Participants
n=146 Participants
|
|
Sex: Female, Male
Male
|
75 Participants
n=39 Participants
|
82 Participants
n=41 Participants
|
72 Participants
n=35 Participants
|
35 Participants
n=31 Participants
|
264 Participants
n=146 Participants
|
|
Region of Enrollment
Japan
|
63 participants
n=39 Participants
|
64 participants
n=41 Participants
|
61 participants
n=35 Participants
|
33 participants
n=31 Participants
|
221 participants
n=146 Participants
|
|
Region of Enrollment
Taiwan
|
34 participants
n=39 Participants
|
37 participants
n=41 Participants
|
38 participants
n=35 Participants
|
16 participants
n=31 Participants
|
125 participants
n=146 Participants
|
|
Region of Enrollment
Korea, Republic of
|
28 participants
n=39 Participants
|
28 participants
n=41 Participants
|
30 participants
n=35 Participants
|
15 participants
n=31 Participants
|
101 participants
n=146 Participants
|
PRIMARY outcome
Timeframe: Baseline and Week 6 [Last Observation Carried Forward (LOCF)]Population: FAS (Full Analysis Set)
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=125 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=129 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=129 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=64 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)
|
-6.1 units on a scale
Standard Deviation 1.75
|
-4.3 units on a scale
Standard Deviation 1.72
|
-2.5 units on a scale
Standard Deviation 1.72
|
-7.1 units on a scale
Standard Deviation 2.44
|
SECONDARY outcome
Timeframe: Baseline and Week 6 (LOCF)Population: FAS (Full Analysis Set)
The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=125 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=129 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=129 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=64 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Change From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)
|
-2.0 units on a scale
Standard Deviation 0.55
|
-1.4 units on a scale
Standard Deviation 0.54
|
-0.6 units on a scale
Standard Deviation 0.54
|
-2.9 units on a scale
Standard Deviation 0.77
|
SECONDARY outcome
Timeframe: Baseline and Week 6 (LOCF)Population: FAS (Full Analysis Set)
The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=125 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=129 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=129 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=64 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Change From Baseline in the PANSS Negative Subscales at Week 6
|
-1.6 units on a scale
Standard Deviation 0.47
|
-1.7 units on a scale
Standard Deviation 0.46
|
-0.9 units on a scale
Standard Deviation 0.46
|
-1.7 units on a scale
Standard Deviation 0.65
|
SECONDARY outcome
Timeframe: Baseline and Week 6 (LOCF)Population: FAS (Full Analysis Set)
The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=125 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=129 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=129 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=64 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Change From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)
|
-2.4 units on a scale
Standard Deviation 0.90
|
-1.2 units on a scale
Standard Deviation 0.88
|
-1.0 units on a scale
Standard Deviation 0.88
|
-2.6 units on a scale
Standard Deviation 1.25
|
SECONDARY outcome
Timeframe: From Baseline to up to 8 weeksPopulation: Safety population defined as subjects who receive at least one dose of the study drug in the treatment period.
Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a study participant who was taking a medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=127 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=131 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=132 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=65 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
|
105 Participants
|
103 Participants
|
101 Participants
|
53 Participants
|
SECONDARY outcome
Timeframe: From Baseline to up to 8 weeksPopulation: Safety population defined as subjects who receive at least one dose of the study drug in the treatment period.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=127 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=131 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=132 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=65 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Proportion of Participants With TEAEs Leading to Discontinuation
|
18 Participants
|
18 Participants
|
27 Participants
|
7 Participants
|
SECONDARY outcome
Timeframe: From Baseline to up to 8 weeksPopulation: Safety population defined as subjects who receive at least one dose of the study drug in the treatment period.
Proportion of participants with treatment-emergent adverse events. An adverse event was considered serious if it met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required in-patient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Was considered to be an important medical event.
Outcome measures
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=127 Participants
SM-13496 40 mg was administered orally once daily.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=131 Participants
SM-13496 80 mg was administered orally once daily.
|
Placebo Group
n=132 Participants
Placebo was administered orally twice daily.
|
Risperidone Group
n=65 Participants
Risperidone was administered orally twice daily.
|
|---|---|---|---|---|
|
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
|
8 Participants
|
7 Participants
|
10 Participants
|
2 Participants
|
Adverse Events
SM-13496 (Lurasidone HCl) 40-mg Group
SM-13496 (Lurasidone HCl) 80-mg Group
Placebo Group
Risperidone Group
Serious adverse events
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=127 participants at risk
SM-13496 40 mg was administered orally once daily, for 6 weeks.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=131 participants at risk
SM-13496 40 mg was administered orally once daily on Days 1 to 7, SM-13496 60 mg on Days 8 to 14, and SM-13496 80 mg on Days 15 to 42.
|
Placebo Group
n=132 participants at risk
Placebo was administered orally twice daily for 6 weeks.
|
Risperidone Group
n=65 participants at risk
Risperidone 2 mg was administered orally twice daily on Days 1 to 7, risperidone 3 mg on Days 8 to 14, and risperidone 4 mg on Days 15 to 42.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Sudden death
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Cellulitis
|
0.79%
1/127 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Convulsion
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Neuroleptic malignant syndrome
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Schizophrenia
|
2.4%
3/127 • Number of events 3 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • Number of events 2 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.5%
6/132 • Number of events 6 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Psychotic disorder
|
2.4%
3/127 • Number of events 3 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • Number of events 2 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.79%
1/127 • Number of events 1 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
Other adverse events
| Measure |
SM-13496 (Lurasidone HCl) 40-mg Group
n=127 participants at risk
SM-13496 40 mg was administered orally once daily, for 6 weeks.
|
SM-13496 (Lurasidone HCl) 80-mg Group
n=131 participants at risk
SM-13496 40 mg was administered orally once daily on Days 1 to 7, SM-13496 60 mg on Days 8 to 14, and SM-13496 80 mg on Days 15 to 42.
|
Placebo Group
n=132 participants at risk
Placebo was administered orally twice daily for 6 weeks.
|
Risperidone Group
n=65 participants at risk
Risperidone 2 mg was administered orally twice daily on Days 1 to 7, risperidone 3 mg on Days 8 to 14, and risperidone 4 mg on Days 15 to 42.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Stomatitis
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Cardiac disorders
Bradycardia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Cardiac disorders
Tachycardia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Congenital, familial and genetic disorders
Dermoid cyst
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Ear and labyrinth disorders
Ear haemorrhage
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Ear and labyrinth disorders
Otorrhoea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Conjunctivitis
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Asthenopia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Oculogyric crisis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Blepharospasm
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Conjunctivitis allergic
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Ocular hyperaemia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Eye disorders
Vision blurred
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Vomiting
|
8.7%
11/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
9.9%
13/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
8.3%
11/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
6.2%
4/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Constipation
|
7.9%
10/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
8.4%
11/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
10.6%
14/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
18.5%
12/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Nausea
|
7.1%
9/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
4/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.5%
6/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Diarrhoea
|
6.3%
8/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
4/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
6.8%
9/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Dyspepsia
|
3.9%
5/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Salivary hypersecretion
|
2.4%
3/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
4/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
3/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Toothache
|
3.1%
4/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.5%
6/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Gingivitis
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Stomach discomfort
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Dental caries
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Periodontitis
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Anal haemorrhage
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Chapped lips
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Cheilitis
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Schizophrenia
|
11.8%
15/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
19.1%
25/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
18.9%
25/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
15.4%
10/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Epigastric discomfort
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Faecal incontinence
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Lip dry
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Lip ulceration
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Tooth loss
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Breath odour
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Oesophageal discomfort
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Pyrexia
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
4/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.8%
5/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Malaise
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Oedema peripheral
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Asthenia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Fatigue
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Irritability
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Thirst
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Chest discomfort
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Chest pain
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
General disorders
Secretion discharge
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Immune system disorders
Allergy to arthropod sting
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Nasopharyngitis
|
10.2%
13/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
9.9%
13/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
9.8%
13/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
13.8%
9/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
3/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Adenoviral conjunctivitis
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Carbuncle
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Eyelid infection
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Hordeolum
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Paronychia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Purulence
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Viral infection
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Dermatitis infected
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Eye infection
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Furuncle
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Tinea pedis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Excoriation
|
3.1%
4/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
4/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Contusion
|
3.1%
4/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Scratch
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Arthropod sting
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Back injury
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Bite
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Device breakage
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Face injury
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Mouth injury
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Nail avulsion
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Periorbital haematoma
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
3/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Foreign body trauma
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Injury, poisoning and procedural complications
Urethral injury
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood creatine phosphokinase increased
|
3.1%
4/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Weight increased
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Alanine aminotransferase increased
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Weight decreased
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.8%
5/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood pressure decreased
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood pressure increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood triglycerides increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Protein urine present
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Aspartate aminotransferase increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood glucose increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood prolactin increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
7.7%
5/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood uric acid increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Glucose urine present
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Platelet count increased
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
White blood cell count increased
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Blood potassium increased
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Deoxypyridinoline urine increased
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Anorexia
|
4.7%
6/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Increased appetite
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Oral intake reduced
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Muscle rigidity
|
3.1%
4/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
6.2%
4/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
2.4%
3/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Akathisia
|
8.7%
11/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
11.5%
15/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.5%
6/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
13.8%
9/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Headache
|
6.3%
8/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
8.4%
11/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
7.6%
10/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
3/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Tremor
|
2.4%
3/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
7.6%
10/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
6.1%
8/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
7.7%
5/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Somnolence
|
3.1%
4/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
6/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Dyskinesia
|
2.4%
3/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.8%
5/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Dystonia
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
6/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
3/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Parkinsonian gait
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.8%
5/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Dizziness
|
2.4%
3/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Sedation
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Bradykinesia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
4.6%
3/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Convulsion
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Dysarthria
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Syncope
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Autism
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Dizziness postural
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Drooling
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Parkinsonism
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Nervous system disorders
Tardive dyskinesia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Insomnia
|
14.2%
18/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
19.1%
25/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
14.4%
19/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
6.2%
4/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Psychotic disorder
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Agitation
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Aggression
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.8%
5/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.1%
2/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Depressive symptom
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Sleep disorder
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Abnormal behaviour
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Dissociative disorder
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Reproductive system and breast disorders
Amenorrhoea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Reproductive system and breast disorders
Dysmenorrhoea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Reproductive system and breast disorders
Galactorrhoea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Reproductive system and breast disorders
Menstruation delayed
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.8%
5/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Rash
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
2.3%
3/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
3.0%
4/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Dermatitis atopic
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Eczema asteatotic
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Haemorrhage subcutaneous
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Cold sweat
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Dermatitis bullous
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Prurigo
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Rash papular
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Skin and subcutaneous tissue disorders
Skin discomfort
|
0.00%
0/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
1/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Vascular disorders
Hypertension
|
1.6%
2/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.76%
1/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
1.5%
2/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
|
Vascular disorders
Haemorrhage
|
0.79%
1/127 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/131 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/132 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
0.00%
0/65 • From Baseline to up to 8 weeks
Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
|
Additional Information
Regional Function Head of CNS Research
Clinical Research, Drug Development Division
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place